Fragment-based drug design (FBDD) has gained immense popularity as a platform for identifying lead candidates in drug discovery programs. To harness its potential, sensitive biophysical technologies are crucial for detecting low affinity interactions of low molecular weight compounds.
This application note showcases the Octet® SF3 system with OneStep® Injections, offering an extraordinary advantage over other SPR-based biosensor technologies. With this cutting-edge system, you can directly influence the rate at which fragment screening is accomplished, accelerating the process of detection and characterization of fragment binding events.
Download this app note now to learn how you can improve your fragment screening workflow.
